Story thread · 2 reports / 2 sources
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:
financialpost.com · 1d
Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination Lucid-MS Advances Novel Disease-Modifying Approach Targeting Multi-Billion Dollar Progressive MS Market with Significant Unmet Medical Need Worldwide TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), […]
First report: Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis: — thestar.com, 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.